Evidence-audited guides decoding FDA food-effect bioavailability studies ("Take With Food"), FDA Orange Book 80%–125% generic bioequivalence (3.5% mean AUC difference across 2,070 human studies), and AHRQ 15-minute doctor visit question checklists. Explore 188 indexed studies and multi-trial syntheses with verified PubMed PMIDs, participant sample sizes (N), and Absolute vs. Relative Risk numbers.
The Plain-English Receipt: Only 1.2% of prediabetic adults on Tirzepatide progressed to Type 2 diabetes over 3.4 years vs. 19.3% on placebo (Absolute Risk Reduction = 18.1% • Number Needed to Treat = 6).
The FDC formulations demonstrated similar bioavailability to coadministered commercially available amlodipine and rosuvastatin.
The US Food and Drug Administration (FDA) authorized the first wearable device that continuously monitors ketone levels in people with type 1 diabetes.
Coral Gables, FL - Snack Right Super Foods, Inc., doing business as Brad's Raw Chips, is recalling certain Brad's Plant Based Crunchy Kale (2 oz) and Brad's Veggie Chips Kale (3 oz) products because they may contain thallium.
Vitality Works Inc. of Albuquerque, New Mexico, is recalling one lot (lot number 2025-26227) of 365 Whole Foods Market Standardized + Full Spectrum Blend Ashwagandha Capsules 120 count because it has the potential to be contaminated with Salmonella, an organis
SLR Food Distribution Inc. of Hicksville, New York, is voluntarily recalling Wise Wife Brand Ground Cinnamon because it has the potential to be contaminated with elevated levels of lead.
10/22/2026, Vitamin Cottage Natural Food Markets, Inc., Lakewood, Colorado, is recalling Natural Grocers Brand Organic 2-Pound Mung Beans due to the potential presence of glass.
October 22, 2026 - WinCo Foods of Boise, ID is recalling the following WinCo Foods Brand Hoagie Rolls due to undeclared sesame.
The U.S. Food and Drug Administration (FDA) is alerting health care providers about import alerts for certain medical devices manufactured in Japan by Olympus Medical Systems Corporation (Olympus) and its subsidiaries.
Traditional health headlines often exaggerate findings by reporting only Relative Risk Reduction—for example, claiming a drug cuts risk by 50% when the event rate dropped from 2% to 1% (an Absolute Risk Reduction of just 1.0 percentage point, meaning 100 patients must take the drug for 1 person to benefit, or NNT = 100). On dotMD, every flagship study breakdown reports both Relative Risk and Absolute Risk alongside the exact sample size (N) and trial duration.
Every study on dotMD displays its exact Study Design Tier at the top of the card (Phase 3 Randomized Trial, Randomized Controlled Trial, Meta-Analysis & Systematic Review, Multi-Trial Clinical Evidence Synthesis, Journal Watch Cohort, or FDA Safety Alert) along with the human participant count (N). Preclinical mouse or cell-culture data is never presented as human clinical proof.
Arbitrary 0-to-100 rigor scores obscure what actually makes a study trustworthy. Instead of synthetic scores, dotMD surfaces the verifiable primary evidence signals: exact NCBI PubMed IDs (PMID), ClinicalTrials.gov registration numbers (NCT), double-blind vs. crossover design, sample size (N), p-values / Hazard Ratios, and study limitations.
Medical research is only useful if you can act on it safely with your clinician. Every flagship research synthesis links directly to the parent Condition diagnostic cutoff guide, the Medication FDA DailyMed & CMS NADAC wholesale price ledger, the Supplement elemental weight decoder, and our High-CPT-Volume Specialist Directory.
